A Case Report of Inflammatory Nonscarring Alopecia Associated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

    Marinya Pongpudpunth, Marie France Demierre, Lynne J. Goldberg
    Studysummary This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results